Evidence map›Paper›PMID 33506106›Full record

ArticleOpen medicine (Warsaw, Poland)2021

TRIM25 contributes to the malignancy of acute myeloid leukemia and is negatively regulated by microRNA-137.

Sheng Wang, Bang Shuo Zhang, Yi Yang, Ying Li, Jing Long Lv, Yu Cheng

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Open medicine (Warsaw, Poland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Sheng WangDepartment of Hematology, Three Gorges Hospital Affiliated to Chongqing University, Chongqing, 404000, China.
Bang Shuo ZhangDepartment of Hematology, Three Gorges Hospital Affiliated to Chongqing University, Chongqing, 404000, China.
Yi YangDepartment of Hematology, Three Gorges Hospital Affiliated to Chongqing University, Chongqing, 404000, China.
Ying LiDepartment of Hematology, Three Gorges Hospital Affiliated to Chongqing University, Chongqing, 404000, China.
Jing Long LvDepartment of Hematology, Three Gorges Hospital Affiliated to Chongqing University, Chongqing, 404000, China.
Yu ChengDepartment of Gastroenterology, Three Gorges Hospital Affiliated to Chongqing University, No. 165 Xincheng Road, Wanzhou District, Chongqing, 404000, China.
Chongqing University · CNChongqing Three Gorges University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcute myeloid leukemia (AML) is a ubiquitous malignancy that occurs in the hematological system. Tripartite motif-containing 25 (TRIM25) has been found to be involved in various carcinomas comprising AML. However, the function and underlying causative role of TRIM25 in AML are still obscure. METHODS AND MATERIALS: Quantitative real-time polymerase chain reaction (qPCR) was used for assaying TRIM25 and miR-137 expression in AML samples and cells. CCK-8 assay, Calcein-acetoxymethylester/propidium iodide staining, and Transwell assay were adopted to assay cell proliferation, invasion, and migration. Dual-luciferase reporter experiment was used for analyzing the interaction of TRIM25 with miR-137. Western blot was used for assaying protein expression levels.

resultsThis study confirmed that TRIM25 expression was upregulated in AML samples and cell lines, whereas miR-137 expression was downregulated. Overexpression of TRIM25 significantly contributed to AML cell's proliferation, invasion, and migration, whereas knockdown exerted the opposite effect. In addition, TRIM25 was a downstream target of miR-137 in AML cells and negatively modulated by miR-137.

conclusionTRIM25 was targeted and regulated by miR-137, exerted a carcinogenic function in AML, and could be used as a latent biomarker and a treatment target for AML.

Indexed as

acute myeloid leukemiametastasismiR-137proliferationTRIM25

Identifiers

PMID33506106
PMCPMC7801882
OpenAlexW3120686916

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.